Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Novartis (NVS - Snapshot Report) recently received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pipeline candidate BYM338. The designation was granted for sporadic inclusion body myositis (sIBM).

This designation should speed up the development and review process for the candidate.

The designation was based on positive results from a phase II study wherein it was observed that BYM338 substantially benefited patients with sIBM compared to placebo.

Novartis is developing BYM338 in collaboration with Morphosys. We note that BYM338 was granted orphan drug designation for the sIBM indication in the U.S. as well as in Europe in 2012.

BYM338 is also being evaluated for the treatment of chronic obstructive pulmonary disease (COPD), cancer cachexia, sarcopenia and in mechanically ventilated patients.

We note that Novartis already has Arcapta Neohaler/Onbrez Breezhaler and Seebri Breezhaler in its kitty indicated for the treatment of COPD.

Last month, Novartis received a positive opinion from the CHMP on Ultibro Breezhaler as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

We are encouraged by the recent pipeline progress at Novartis. We remind investors that Novartis upped its 2013 guidance based on a solid performance in the first half and lower-than-expected generic erosion. The delayed entry of generic Diovan Mono in the U.S. continues to positively impact results.

Novartis now expects sales to increase in the low single digits in 2013 as compared to the earlier expectation of being in line with 2012. Sales in the Pharmaceutical Division are expected to be in line with 2012 compared to the previous estimate of a low single-digit decline.

Novartis currently carries a Zacks Rank #3 (Hold). Right now, Ironwood Pharmaceuticals (IRWD - Analyst Report), Shire (SHPG - Analyst Report), and Jazz Pharmaceuticals (JAZZ - Analyst Report) look attractive, each carrying a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%